Pathology of Parkinson’s disease
10.1007/bf03159935
Crossref journal-article
Springer Science and Business Media LLC
Molecular and Chemical Neuropathology (297)
Bibliography

Jellinger, K. A. (1991). Pathology of Parkinson’s disease. Molecular and Chemical Neuropathology, 14(3), 153–197.

Authors 1
  1. Kurt A. Jellinger (first)
References 263 Referenced 438
  1. Agid Y., Javoy-Agid F., and Ruberg M. (1987) Biochemistry of neurotransmitters in Parkinson’s disease,Movement Disorders 2 (Marsden C. D. and Fahn S. T., eds.), pp. 166–230, Butterworth, London. / Movement Disorders 2 by Y. Agid (1987)
  2. Agid Y., Graybiel A. M., Ruberg M., Hirsch E., Blin J., Dubois B., and Javoy-Agid F. (1990) The efficacy of levodopa treatment declines in the course of Parkinson’s disease: Do nondopaminergic lesions play a role?Adv. Neurol. 53, 83–100. / Adv. Neurol. by Y. Agid (1990)
  3. Albanese A., Altavista M. C., Gozzo S., Rossi P., Colosimo C., Bentivoglio A. R., Rerretta G., Elia M., Monaco V., and Macchi G. (1990) Chronic administration of MPTP to marmosets.Adv. Neurol. 53, 239–249. / Adv. Neurol. by A. Albanese (1990)
  4. Albin R. L., Young A. B., and Penney J. B. (1989) The functional anatomy of basal ganglia disorders.Trends Neurosci. 12, 366–374. (10.1016/0166-2236(89)90074-X) / Trends Neurosci. by R. L. Albin (1989)
  5. Alexander G. E., DeLong M. R., and Strick P. L. (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex.Annu. Rev. Neuroscience 9, 357–381. (10.1146/annurev.ne.09.030186.002041) / Annu. Rev. Neuroscience by G. E. Alexander (1986)
  6. Allen J. M., Cross A. J., Crow T. J., Javoy-Agid F., Agid Y., and Bloom S. R. (1985) Dissociation of NPY and somatostatin in Parkinson disease.Brain Res. 337, 197–202. (10.1016/0006-8993(85)91632-4) / Brain Res. by J. M. Allen (1985)
  7. Allen J. M., Cross, A. J., Yeats, J. C., Ghatel, M. A., McGregor, G. F., and Close, S. P. (1986) Neuropeptides and dopamine in the marmoset—Effect of treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): An animal model for Parkinson’s disease.Brain 109, 143–157. (10.1093/brain/109.1.143) / Brain by J. M. Allen (1986)
  8. Allen S. J., Dawbarn D., and Wilcock G. K. (1988) Morphometric immunochemical analysis of neurons in the nucleus basalis of Meynert in Alzheimer’s disease.Brain Res. 454, 275–281. (10.1016/0006-8993(88)90827-X) / Brain Res. by S. J. Allen (1988)
  9. Arai H., Kosaka K., and Iizuka R. (1984a) Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer type dementia.J. Neurochem. 43, 388–393. (10.1111/j.1471-4159.1984.tb00913.x) / J. Neurochem. by H. Arai (1984)
  10. Arai H., Moroji T., and Kosaka K. (1984b) Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer type dementia.Neurosci. Lett. 52, 73–78. (10.1016/0304-3940(84)90353-7) / Neurosci. Lett. by H. Arai (1984)
  11. Arendt A., Bigl V., and Tennstedt A. (1985) Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical area in Alzheimer’s disease.Neuroscience 14, 1–14. (10.1016/0306-4522(85)90160-5) / Neuroscience by A. Arendt (1985)
  12. Arendt T., Bigl V., Arendt A., and Tennstedt A. (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease.Acta Neuropathol. (Berl.) 61, 101–108. (10.1007/BF00697388) / Acta Neuropathol. (Berl.) by T. Arendt (1983)
  13. Arendt T., Taubert G., Bigl V., and Arendt A. (1988) Amyloid deposition in the nucleus basalis of Meynert complex: A topographic marker for degenerating cell clusters in Alzheimer’s disease.Acta Neuropathol. (Berl.) 75, 226–232. (10.1007/BF00690530) / Acta Neuropathol. (Berl.) by T. Arendt (1988)
  14. Arendt T., Zveginsev H. G., and Leontovich T. A. (1986) Dendritic changes in the nucleus basalis of Menyert and in the diagonal band nucleus in Alzheimer’s disease. A quantitative Golgi investigation.Neuroscience 19, 1265–1278. (10.1016/0306-4522(86)90141-7) / Neuroscience by T. Arendt (1986)
  15. Armstrong D. M., Benzing W. C., Evans J., Terry R. D., Shields D., and Hansen L. A. (1989) Substance P and somatostatin coexist within neuritic plaques: Implications for the pathogenesis of Alzheimer’s disease.Neuroscience 31, 663–671. (10.1016/0306-4522(89)90431-4) / Neuroscience by D. M. Armstrong (1989)
  16. Bancher C., Lassmann H., Budka H., Jellinger K., Grundke-Iqbal I., Iqbal K., Wiche G., Seitelberger F., and Wisniewski H. M. (1989) Antigenic profile of Lewy bodies: Immunocytochemical evidence for protein phosphorylation and ubiquitination.J. Neuropathol. Exp. Neurol. 48, 81–93. (10.1097/00005072-198901000-00007) / J. Neuropathol. Exp. Neurol. by C. Bancher (1989)
  17. Beal M. F., and Martin J. B. (1986) Neuropeptides in neurological disease.Ann. Neurol. 20, 547–565. (10.1002/ana.410200502) / Ann. Neurol. by M. F. Beal (1986)
  18. Beal M. F., Clevens R. A., and Mazurek M. F. (1988) Somatostatin and neuropeptide Y immunoreactivity in Parkinson’s disease dementia with Alzheimer’s changes.Synapse 2, 463–467. (10.1002/syn.890020415) / Synapse by M. F. Beal (1988)
  19. Beal M. F., Mazurek F., Chattha G. K., Svedsen C. N., Bird E. D., and Martin J. B. (1986) Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer’s disease.Ann. Neurol. 20, 282–288. (10.1002/ana.410200303) / Ann. Neurol. by M. F. Beal (1986)
  20. Beal M. F., Mazurek M. F., and Tran V. T. (1985) Somatostatin receptors are reduced in cerebral cortex in Alzheimer’s disease.Science 229, 289–291. (10.1126/science.2861661) / Science by M. F. Beal (1985)
  21. Beckstead R. M. (1987) Striatal substance P cell clusters coincide with the high density terminal zones of the discontinuous nigrostriatal dopaminergic projection system in the cat.Neuroscience 20, 557–576. (10.1016/0306-4522(87)90110-2) / Neuroscience by R. M. Beckstead (1987)
  22. Bender M. B. (1980) Brain control of conjugate horizontal and vertical eye movements.Brain 103, 25–69. (10.1093/brain/103.1.23) / Brain by M. B. Bender (1980)
  23. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger, F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical morphological and neurochemical correlations.J. Neurol. Sci. 20, 415–455. (10.1016/0022-510X(73)90175-5) / J. Neurol. Sci. by H. Bernheimer (1973)
  24. Bigl V., Arendt T., Fischer S., Werner M., and Arendt A. (1987) The cholinergic system in aging.Gerontology 33, 172–180. (10.1159/000212872) / Gerontology by V. Bigl (1987)
  25. Birkmayer W. and Riederer P. (1985)Die Parkinson-Krankheit 2nd Ed. (Springer, Wien). (10.1007/978-3-7091-2262-4) / Die Parkinson-Krankheit by W. Birkmayer (1985)
  26. Birkmayer W. and Riederer P. (1986) Biological aspects of depression in Parkinson’s disease.Psychopathology 19 (Suppl.) 2, 58–61. (10.1159/000285133) / Psychopathology by W. Birkmayer (1986)
  27. Bissette G., Nemeroff C. R., Decker M. W., Kizer J. S., Agid Y., and Javoy-Agid F. (1985) Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson’s disease.Ann. Neurol. 17, 324–328. (10.1002/ana.410170403) / Ann. Neurol. by G. Bissette (1985)
  28. Bogerts B., Häntsch J., and Herzer M. (1983) A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics.Biol. Psychiatry 18, 951–969. / Biol. Psychiatry by B. Bogerts (1983)
  29. Bondareff W., Mountjoy C. Q., and Roth M. (1982) Loss of neurons of origin of the adrenergic projections to the cerebral cortex (nucleus locus ceruleus) in senile dementia.Neurology 32, 164–168. (10.1212/WNL.32.2.164) / Neurology by W. Bondareff (1982)
  30. Bondareff W., Mountjoy C. Q., Roth M., Rossor M. N., Iversen L. L., Reynolds G. P. and Hauser D. L. (1987) Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease.Alzheimer Dis. Assoc. Disord. 1, 256–262. (10.1097/00002093-198701040-00005) / Alzheimer Dis. Assoc. Disord. by W. Bondareff (1987)
  31. Bowen D. A. (1990) Treatment of Alzheimer’s disease.Br. J. Psychiatry 157, 327–330. (10.1192/bjp.157.3.327) / Br. J. Psychiatry by D. A. Bowen (1990)
  32. Brooks W. J., Jarvis M. F., and Wagner C. (1989) Astrocytes as a primary locus for the conversion of MPTP into MPP+.J. Neural Transm. 76, 1–12. (10.1007/BF01244987) / J. Neural Transm. by W. J. Brooks (1989)
  33. Burke W. J., Chung H. D., Huang J. S., Grossberg G. T. and Joh T. H. (1988) Evidence for retrograde degeneration of epinephrine neurons in Alzheimer’s disease.Ann. Neurol. 24, 532–536. (10.1002/ana.410240409) / Ann. Neurol. by W. J. Burke (1988)
  34. Candy J. M., Perry R. H., Perry E. K., Irving D., Blessed G., Fairbairn A. F., and Tomlinson, B. E. (1983) Pathological changes in the nucleus basalis of Meynert in Alzheimer’s and Parkinson’s disease.J. Neurol. Sci. 54, 277–289. (10.1016/0022-510X(83)90045-X) / J. Neurol. Sci. by J. M. Candy (1983)
  35. Candy J. M., Gascoigne A. D., Biggins A., Smith I., Perry R. H., Perry E. K., McDermott J. R., and Edwardson J. E. (1985) Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer’s disease.J. Neurol. Sci. 71, 315–323. (10.1016/0022-510X(85)90070-X) / J. Neurol. Sci. by J. M. Candy (1985)
  36. Carmichael S. W., Wilson R. J., Brimijoin W. S., Melton L. J., Okazaki J., Yaksh T., Ahlskog J. E., Stoddard S. L., and Tyce G. M. (1988) Decreased catecholamines in the adrenal medulla of patients with parkinsonism.New Engl. J. Med. 319, 254. / New Engl. J. Med. by S. W. Carmichael (1988)
  37. Cash R., Dennis R., L’Heureux R., Raisman R., Javoy-Agid F., and Scatton B. (1987) Parkinson’s disease and dementia: Norepinephrine and dopamine in locus ceruleus.Neurology 37, 42–46. (10.1212/WNL.37.1.42) / Neurology by R. Cash (1987)
  38. Chan-Palay V. (1987) Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: Coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia.J. Comp. Neurol. 260, 201–223. (10.1002/cne.902600205) / J. Comp. Neurol. by V. Chan-Palay (1987)
  39. Chan-Palay V., Allen Y. S., Lang W., Haesler U., and Polak J. M. (1985) Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer’s type dementia.J. Comp. Neurol 238, 382–390. (10.1002/cne.902380403) / J. Comp. Neurol by V. Chan-Palay (1985)
  40. Chan-Palay V. and Asan E. (1989a) Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression.J. Comp. Neurol. 287, 357–372. (10.1002/cne.902870307) / J. Comp. Neurol. by V. Chan-Palay (1989)
  41. Chan-Palay V. and Asan E. (1989b) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of Alzheimer type and in Parkinson’s disease with and without dementia and depression.J. Comp. Neurol. 287, 373–392. (10.1002/cne.902870308) / J. Comp. Neurol. by V. Chan-Palay (1989)
  42. Chan-Palay V., Köhler C., Haesler U., Lang W., and Yasargil G. (1986) Distribution of altered hippocampal neurons and axons immunoreactive with antisera against Neuropeptide Y in Alzheimer’s type dementia.J. Comp. Neurol. 248, 360–375. (10.1002/cne.902480306) / J. Comp. Neurol. by V. Chan-Palay (1986)
  43. Chan-Palay V., Köhler C., and Höchli M. (1989) Coexistence of somatostatin and neuropeptide Y in the hippocampus of patients with Alzheimer’s and Parkinson’s disease,The hippocampus—New vistas pp. 513–534, A. R. Liss, New York. / The hippocampus—New vistas by V. Chan-Palay (1989)
  44. Chinaglia G., Probst A., and Palacios J. M. (1990) Neurotensin receptors in Parkinson’s disease and progressive supranuclear palsy: An autoradiographic study in basal ganglia.Neuroscience 19, 351–360. (10.1016/0306-4522(90)90273-7) / Neuroscience by G. Chinaglia (1990)
  45. Chui H. C., Mortimer J. A., Slager U., Barrow C., Bonareff W., and Webster D. D. (1986) Pathological correlates of dementia in Parkinson’s disease.Arch. Neurol. 43, 991–995. (10.1001/archneur.1986.00520100013007) / Arch. Neurol. by H. C. Chui (1986)
  46. Coles S. K., Iles J. F., and Nicolopoulos-Stournaras S. (1989) The mesencephalic centre controlling locomotion in the rat.Neuroscience 28, 149–157. (10.1016/0306-4522(89)90239-X) / Neuroscience by S. K. Coles (1989)
  47. Constantinidis J., Bouras C., and Vallet P. G. (1988) Neuropeptides in Alzheimer’s and in Parkinson’s disease.Mt. Sinai J. Med. 55, 102–115. / Mt. Sinai J. Med. by J. Constantinidis (1988)
  48. Cross A. J., Crow T. J., Ferier I. N., Johnson A. J., Bloom S. R. and Corsellis J. A. N. (1984) Serotonin receptor changes in dementia of the Alzheimer type.J. Neurochem. 43, 1574–1581. (10.1111/j.1471-4159.1984.tb06081.x) / J. Neurochem. by A. J. Cross (1984)
  49. Crow T. J., Cross A. J., Cooper S. J., Deakin J. F., Ferrier I. N., Johnson J. A., Joseph M. H., Owen F., Poulter M., and Lofthouse R. (1984) Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides.Neuropharmacology 23, 1561–1569. (10.1016/0028-3908(84)90100-X) / Neuropharmacology by T. J. Crow (1984)
  50. Curcio C. A. and Kemper T. (1984) Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density.J. Neuropathol. Exp. Neurol. 43, 359–368. (10.1097/00005072-198407000-00001) / J. Neuropathol. Exp. Neurol. by C. A. Curcio (1984)
  51. D’Amato R. J., Zweig R. M., Whitehouse P. J., Wenk G. L., Singer H. S., Mayeux R., Price D. L., and Snyder S. H. (1987) Aminergic systems in Alzheimer’s disease and Parkinson’s disease.Ann. Neurol. 22, 229–236. (10.1002/ana.410220207) / Ann. Neurol. by R. J. D’Amato (1987)
  52. Davies P. (1988) Neurochemical studies: An update on Alzheimer’s disease.J. Clin. Psychiatry 49 (Suppl.), 23–28. / J. Clin. Psychiatry by P. Davies (1988)
  53. Davies P., Katzman R., and Terry R. D. (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease.Nature 288, 279. (10.1038/288279a0) / Nature by P. Davies (1980)
  54. Davis G. C., Williams A. C., Markey S. P., Ebert M. H., Reichert C. M., and Kopin I. J. (1979) Parkinsonism secondary to intravenous injection of meperidine analogues.Psychiatr. Res. 1, 249–254. (10.1016/0165-1781(79)90006-4) / Psychiatr. Res. by G. C. Davis (1979)
  55. Dawbarn D., Rossor M. N., Mountjoy C. Q., Roth M., and Emson P. C. (1986) Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in dementia of Alzheimer type.Neurosci. Lett. 70, 154–159. (10.1016/0304-3940(86)90455-6) / Neurosci. Lett. by D. Dawbarn (1986)
  56. Dickson D. W., Crystal H., Mattiace L. A. (1989) Diffuse Lewy body disease: Light and electron microscopic immunocytochemistry of senile plaques.Acta Neuropathol. (Berl.) 78, 572–584. (10.1007/BF00691284) / Acta Neuropathol. (Berl.) by D. W. Dickson (1989)
  57. Dietl M. M., Probst A., and Palacios J. M. (1987) On the distribution of cholecystokinin receptor binding sites in the human brain. An autoradiographic study.Synapse 1, 169–183. (10.1002/syn.890010205) / Synapse by M. M. Dietl (1987)
  58. Doucette R., Fisman M., Hachinski V. C., and Mersky H. (1986) Cell loss from the nucleus basalis of Meynert in Alzheimer disease.Can. J. Neurol. Sci. 13, 435–440. (10.1017/S0317167100037070) / Can. J. Neurol. Sci. by R. Doucette (1986)
  59. Dubois B., Pillon B., Lhermitte F., and Agid Y. (1990) Cholinergic deficiency and frontal dysfunction in Parkinson’s disease.Ann. Neurol. 28, 117–121. (10.1002/ana.410280202) / Ann. Neurol. by B. Dubois (1990)
  60. Dubois B., Hauw J. J., Ruberg M., Serdaru M., Javoy-Agid F., and Agid Y. (1985) Démence et maladie de Parkinson: Correlations biochimiques et anatomo-cliniquesRev. Neurol. (Paris) 141, 184–193. / Rev. Neurol. (Paris) by B. Dubois (1985)
  61. Eadie M. J. (1963) The pathology of certain medullary nuclei in parkinsonism.Brain 86, 781–795. (10.1093/brain/86.4.781) / Brain by M. J. Eadie (1963)
  62. Epelbaum J. (1983) Somatostatin in the central nervous system: Physiology and pathological modifications.Progr. Neurobiol. 27, 63–100. (10.1016/0301-0082(86)90012-2) / Progr. Neurobiol. by J. Epelbaum (1983)
  63. Epelbaum J., Javoy-Agid F., Enjalbert A., Krantic S., Kordon C., and Agid Y. (1988) Somatostatin concentrations and binding sites in human frontal cortex are differently affected in Parkinson’s disease associated with dementia and supranuclear palsy.J. Neurol. Sci. 87, 167–174. (10.1016/0022-510X(88)90242-0) / J. Neurol. Sci. by J. Epelbaum (1988)
  64. Epelbaum J., Ruberg M., Moyse E, Javoy-Agid F., Dubois B., and Agid Y. (1983) Somatostatin and dementia in Parkinson’s disease.Brain Res. 278, 376–397. (10.1016/0006-8993(83)90277-9) / Brain Res. by J. Epelbaum (1983)
  65. Esiri M. M., Pearson R. C. A., Steele J. E., Bowen D. M., and Powell T. P. S. (1990) A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer’s disease.J. Neurol. Neurosurg. Psychiatry 53, 161–165. (10.1136/jnnp.53.2.161) / J. Neurol. Neurosurg. Psychiatry by M. M. Esiri (1990)
  66. Etienne P., Robitaille Y., Wood P., Gauthier S., Nair N. P. V., and Quirion R. (1986) Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer’s disease.Neuroscience 19, 1279–1291. (10.1016/0306-4522(86)90142-9) / Neuroscience by P. Etienne (1986)
  67. Ezrin-Waters C. and Resch L. (1986) The nucleus basalis of Meynert.Can. J. Neurol. Sci. 13, 8–14. (10.1017/S0317167100035721) / Can. J. Neurol. Sci. by C. Ezrin-Waters (1986)
  68. Ferrier I. N. and Leake A. (1990) Peptides in the neocortex in Alzheimer’s disease and aging.Psychoneuroendocrinology 15, 89–96. (10.1016/0306-4530(90)90017-4) / Psychoneuroendocrinology by I. N. Ferrier (1990)
  69. Foote S. L., Bloom F. E., and Aston-Jones G. (1983) Nucleus locus ceruleus: New evidence of anatomical and physiological specificity.Physiol. Rev. 63, 844–914. (10.1152/physrev.1983.63.3.844) / Physiol. Rev. by S. L. Foote (1983)
  70. Forno L. S. (1986) The Lewy body in Parkinson’s disease.Adv. Neurol. 45, 35–43. / Adv. Neurol. by L. S. Forno (1986)
  71. Forno L. S. (1990) Neuropathology of MPTP-induced parkinsonism in animals,Abstr., XIth International Congress of Neuropathology, Kyoto, Sept. 2–8, 1990, p. 5.
  72. Forno L. S. and Norville R. L. (1979) Ultrastructure of the neostriatum in Huntington’s and Parkinson’s disease.Adv. Neurol. 23, 123–135. / Adv. Neurol. by L. S. Forno (1979)
  73. Forno L. S., Gardiner R. E., and Eng L. F. (1985) Somatostatin-like immunoreactivity in the human basal ganglia (abstract).J. Neuropathol. Exp. Neurol. 44, 326. (10.1097/00005072-198505000-00066) / J. Neuropathol. Exp. Neurol. by L. S. Forno (1985)
  74. Forno L. S., Langston J. W., DeLanney L. E., and Irwin I. (1988) An electron microscopic study of MPTP-induced inclusion bodies in old monkey.Brain Res. 448, 150. (10.1016/0006-8993(88)91111-0) / Brain Res. by L. S. Forno (1988)
  75. Forno L. S., Langston J. W., DeLanney L. E., Irwin I., and Ricaurte G. A. (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.Ann. Neurol. 20, 449–455. (10.1002/ana.410200403) / Ann. Neurol. by L. S. Forno (1986)
  76. Foster N. L., Tamminaga C. A., O’Donohue T. L., Tanimoto K., Bird E. D., and Chase T. N. (1986) Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer’s disease.Neurosci. Lett. 63, 71–75. (10.1016/0304-3940(86)90015-7) / Neurosci. Lett. by N. L. Foster (1986)
  77. Francis P. T. and Bowen D. M. (1989) Tacrine, a drug with therapeutic potential for dementia: Postmortem biochemical evidence.Can. J. Neurol. Sci. 16, 504–510. (10.1017/S031716710002984X) / Can. J. Neurol. Sci. by P. T. Francis (1989)
  78. Francis P. T., Bowen D. M., Lowe S. L., Neary D., Mann D. M. A., and Snowden J. S. (1987) Somatostatin content and release measured in cerebral biopsies from demented patients.J. Neurol. Sci. 78, 1–16. (10.1016/0022-510X(87)90073-6) / J. Neurol. Sci. by P. T. Francis (1987)
  79. Gaspar P. and Gray F. (1984) Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases.Acta Neuropathol. (Berl.) 64, 43–52. (10.1007/BF00695605) / Acta Neuropathol. (Berl.) by P. Gaspar (1984)
  80. Gaspar P., Berger B., and Lesur A. (1987) Somatostatin 28 and neuropeptide Y innervation in the septal area and related cortical and subcortical structures of the human brain. Distribution, relationship and evidence for different coexistence.Neuroscience 22, 49–73. (10.1016/0306-4522(87)90197-7) / Neuroscience by P. Gaspar (1987)
  81. German D. C., Dubsch M., Askari S., Speciale S. G., and Bowden D. M. (1988a) 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced parkinsonian syndrome, in Macaca fascicularis: Which midbrain dopaminergic neurons are lost?Neuroscience 24, 161–174. (10.1016/0306-4522(88)90320-X) / Neuroscience by D. C. German (1988)
  82. German D. C., Manaye K., Smith W. K., Woodward D. J., and Saper C. B. (1989) Midbrain catecholaminergic loss in Parkinson’s disease: Computer visualization.Ann. Neurol. 26, 507–514. (10.1002/ana.410260403) / Ann. Neurol. by D. C. German (1989)
  83. German D. C., Manaye K., Smith W. K., White C. L., Woodward D. J., and Mann D. M. A. (1990) Catecholaminergic cell loss in Parkinson’s disease: Computer image,Abstr., XIth International Congress of Neuropathology, Kyoto, Sept. 2–8, 1990, p. 76.
  84. German D. C., Walker B. S., Manaye K., Smith W. K., Woodward D. J., and North A. J. (1988b) The human locus coeruleus: Computer reconstruction of cellular distribution.J. Neurosci. 8, 1776–1788. (10.1523/JNEUROSCI.08-05-01776.1988) / J. Neurosci. by D. C. German (1988)
  85. German D. C., White C. L. III, and Sparkman D. R. (1987) Alzheimer’s disease: Neurofibrillary tangles in nuclei that project to the cerebral cortex.Neuroscience 21, 305–312. (10.1016/0306-4522(87)90123-0) / Neuroscience by D. C. German (1987)
  86. Gertz H. J., Cervos-Navarro J., and Ewald V. (1987) The septo-hippocampal pathway in patients suffering from dementia of Alzheimer’s type. Evidence for neuronal plasticity?Neurosci. Lett. 76, 228–232. (10.1016/0304-3940(87)90720-8) / Neurosci. Lett. by H. J. Gertz (1987)
  87. Geula C. and Mesulam M. M. (1989) Cortical cholinergic fibers in aging and Alzheimer’s disease: A morphometric study.Neuroscience 33, 469–481. (10.1016/0306-4522(89)90399-0) / Neuroscience by C. Geula (1989)
  88. Gibb W. R. G. (1990) Juvenile parkinsonism, dopa-responsive dystonia and nigrostriatal subdivision,Abstr. XIth International Congress Neuropathology, Kyoto, Sept 2–8, 1990, p. 5.
  89. Gibb W. R. G., Fearnley J. M., and Lees A. J. (1990) The anatomy and pigmentation of the human substania nigra in relation to selective neuronal vulnerability.Adv. Neurol. 53, 31–34. / Adv. Neurol. by W. R. G. Gibb (1990)
  90. Gibb W. R. G., Mountjoy C. Q., Mann D. M. A., and Lees A. J. (1989a) The substantia nigra and ventral tegmental areas in Alzheimer’s disease and Down’s syndrome.J. Neurol. Neurosurg. Psychiatry 52, 193–200. (10.1136/jnnp.52.2.193) / J. Neurol. Neurosurg. Psychiatry by W. R. G. Gibb (1989)
  91. Gibb W. R. G., Terruli M., Lees A. J., Jenner P., and Marsden C. D. (1989b) The evolution of morphological changes in the nervous system of the common marmoset following the acute administration of MPTP.Movement Disord. 4, 53–74. (10.1002/mds.870040109) / Movement Disord. by W. R. G. Gibb (1989)
  92. Glowinski J., Michelot R., and Cheramy A. (1980) Role of striatonigral substance P in the regulation of activity of the striatonigral dopaminergic neurones.Neural Peptides and Neuronal Communication (Costa E. and Trabuchi M., eds.), pp. 51–63, Raven, New York. / Neural Peptides and Neuronal Communication by J. Glowinski (1980)
  93. Goto S., Hirano A., and Matsumoto S. (1989) Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson’s disease and striatonigral degeneration.Ann. Neurol. 26, 766–770. (10.1002/ana.410260613) / Ann. Neurol. by S. Goto (1989)
  94. Goto S., Hirano A., and Matsumoto S. (1990) Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson’s and Alzheimer’s diseases.Ann. Neurol. 27, 520–527. (10.1002/ana.410270511) / Ann. Neurol. by S. Goto (1990)
  95. Goudsmit E., Hofman M. A., Fliers E., and Swaab D. F. (1990) The supraoptic and paraventricular nuclei of the human hypothalamus in relation to sex, and Alzheimer’s disease.Neurobiol. Aging 11, 529–536. (10.1016/0197-4580(90)90114-F) / Neurobiol. Aging by E. Goudsmit (1990)
  96. Grafe M. R., Forno L. S., and Eng L. F. (1985) Substance P and met-enkephalin immunoreactivity in Parkinson’s, Huntington’s and Alzheimer’s disease.J Neuropathol. Exp. Neurol. 44, 47–59. (10.1097/00005072-198501000-00004) / J Neuropathol. Exp. Neurol. by M. R. Grafe (1985)
  97. Graybiel A. M. (1986) Neuropeptides in the basal ganglia,Neuropeptides in Neurologic and Psychiatric Disease (Martin J. B. and Barchas J. eds.), pp. 135–161, Raven, New York. / Neuropeptides in Neurologic and Psychiatric Disease by A. M. Graybiel (1986)
  98. Graybiel A. M. (1989) Dopaminergic and cholinergic systems in the striatum.Neural mechanisms in disorders of movement (Crossman A. and Sambrook M. A., eds.), Libbey, London. / Neural mechanisms in disorders of movement by A. M. Graybiel (1989)
  99. Graybiel, A. M., Hirsch E. C., and Agid Y. (1990) The nigrostriatal system in Parkinson’s disease.Adv. Neurol. 53, 17–29. / Adv. Neurol. by A. M. Graybiel (1990)
  100. Guiloff, R. J., George R. J. and Marsden D. C. (1980) Reversible supranuclear ophthalmoplegia associated with parkinsonism.J. Neurol. Neurosurg. Psychiatry 43, 352–354. / J. Neurol. Neurosurg. Psychiatry by R. J. Guiloff (1980)
  101. Halliday G. M., Blumbergs P. C., Cotton R. G. H., Blessing W. W., and Geffen L. B. (1990a) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease.Brain Res. 510, 104–107. (10.1016/0006-8993(90)90733-R) / Brain Res. by G. M. Halliday (1990)
  102. Halliday G. M., Blumbergs P. C., Cotton R. G. H., Howe P. R. C., Blessing W. W., and Geffen L. B. (1990b) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease.Ann. Neurol. 27, 373–385. (10.1002/ana.410270405) / Ann. Neurol. by G. M. Halliday (1990)
  103. Halliday G. M., Gai, W. P., Blessing W. W., and Geffen L. B. (1990c) Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain.Neuroscience 39, 81–96. (10.1016/0306-4522(90)90223-Q) / Neuroscience by G. M. Halliday (1990)
  104. Hallanger A. E., Levey A. L., Lee H. J., Rye D. B., and Wainer B. H. (1987) The origins of cholinergic and other subcortical afferents to the thalamus in the rat.J. Comp. Neurol. 262, 105–124. (10.1002/cne.902620109) / J. Comp. Neurol. by A. E. Hallanger (1987)
  105. Hassler R. (1938) Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus.J. Psychol. Neurol. (Lpz.) 48, 387–476. / J. Psychol. Neurol. (Lpz.) by R. Hassler (1938)
  106. Hedreen J. C., Struble R. G., Whitehouse P. J., and Price D. L. (1984) Topography of the magnocellular basal forebrain system in human brain.J. Neuropathol. Exp. Neurol. 31, 1–21. (10.1097/00005072-198401000-00001) / J. Neuropathol. Exp. Neurol. by J. C. Hedreen (1984)
  107. Heilig C. W., Knopman D. S., Mastri A. R., and Frey W. (1985) Dementia without Alzheimer pathology.Neurology 35, 762–765. (10.1212/WNL.35.5.762) / Neurology by C. W. Heilig (1985)
  108. Hertz L. (1989) Is Alzheimer’s disease an anterograde degeneration, originating in the brainstem, and disrupting metabolic and functional interactions between neurons and glial cells?Brain Res. Rev. 14, 335–353. (10.1016/0165-0173(89)90017-9) / Brain Res. Rev. by L. Hertz (1989)
  109. Hirsch E. C., Graybiel A. M., and Agid Y. A. (1988) Melanized dopaminergic neurons are differently susceptible to degeneration in Parkinson’s disease.Nature 334, 345–348. (10.1038/334345a0) / Nature by E. C. Hirsch (1988)
  110. Hirsch E. C., Graybiel A. M., Duyckaerts C., and Javoy-Agid F. (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson’s disease and progressive supranuclear palsy.Proc. Nat. Acad. Sci. USA 84, 5976–5980. (10.1073/pnas.84.16.5976) / Proc. Nat. Acad. Sci. USA by E. C. Hirsch (1987)
  111. Hökfelt T., Millhorn D., Seroogy K., Tsuruo Y., Ceccatelli S., Lindh B., Meister B., Melander T., Schalling M., Bartfai T., and Terenius L. (1987) Coexistence of peptides with classical neurotransmitters.Experientia 43, 768–780. (10.1007/BF01945354) / Experientia by T. Hökfelt (1987)
  112. Hornykiewicz O. (1975) Parkinson’s disease and its chemotherapy.Biochem. Pharmacol. 24, 1061–1065. (10.1016/0006-2952(75)90190-2) / Biochem. Pharmacol. by O. Hornykiewicz (1975)
  113. Hornykiewicz O. (1989) The neurochemical basis of the pharmacology of Parkinson’s disease,Drugs for the Treatment of Parkinson’s Disease (Calne D. B., ed.),Handbook of Experimental Pharmacology vol. 88, pp. 185–204, Springer, Berlin. (10.1007/978-3-642-73899-9_6) / Drugs for the Treatment of Parkinson’s Disease by O. Hornykiewicz (1989)
  114. Hornykiewicz O., Pifl C., Kish S. J., Shannak K., and Schingnitz G. (1989) Biochemical changes in idiopathic, Parkinson’s disease, aging, and MPTP parkinsonism: Similarities and differences,Parkinsonism and Aging (Calne, D. B., et al., eds.), pp. 57–67, Raven, New York. / Parkinsonism and Aging by O. Hornykiewicz (1989)
  115. Hunter S. (1985) The rostral mesencephalon in Parkinson’s and Alzheimer’s disease.Acta Neuropathol. (Berl.) 68, 326–334. / Acta Neuropathol. (Berl.) by S. Hunter (1985)
  116. Ichimija Y., Arai H., Kosaka K., and Iizuka R. (1986) Morphological and biochemical changes in the cholinergic and monoaminergic system in Alzheimer-type dementia.Acta Neuropathol. (Berl.) 70, 112–116. (10.1007/BF00691428) / Acta Neuropathol. (Berl.) by Y. Ichimija (1986)
  117. Imai H., Steindler D. A., and Kitai S. (1987) The organization of divergent axonal projections from the midbrain raphe nuclei in the rat.J. Comp. Neurol. 243, 363. (10.1002/cne.902430307) / J. Comp. Neurol. by H. Imai (1987)
  118. Ingram V. M., Koenig J. H., Miller C. H., Moore H. E., Blanchard B., and Perry D. E. (1987) The locus coeruleus: Computer assisted 3-dimensional analysis of degeneration in Alzheimer’s and Down’s disease,Alzheimer’s Disease: Advances in Basic Research and Therapy (Wurtman R. J., Corkin, S. H., and Growden J. H. eds.), Center for Brain Science and Metabolism Charitable Trust, Cambridge, pp. 435–440. / Alzheimer’s Disease: Advances in Basic Research and Therapy by V. M. Ingram (1987)
  119. Javoy-Agid F., Hirsch E. C., Dumas S., Duyckaerts C., Mallet J., and Agid Y. (1990) Decreased tysosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson’s disease: An in situ hybridization study.Neuroscience 38, 245–253. (10.1016/0306-4522(90)90389-L) / Neuroscience by F. Javoy-Agid (1990)
  120. Javoy-Agid F., Ploska A., and Agid Y. (1981) Microtopography of tyrosine hydroxylase, glutamic adic decarboxylase and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and parkinsonian brain.J. Neurochem. 37, 1218–1227. (10.1111/j.1471-4159.1981.tb04672.x) / J. Neurochem. by F. Javoy-Agid (1981)
  121. Javoy-Agid F., Ruberg M., Taquer H., Bobobza B., and Agid Y. (1984) Biochemical neuropathology of Parkinson’s disease.Adv. Neurol. 40, 189–197. / Adv. Neurol. by F. Javoy-Agid (1984)
  122. Jellinger K. (1986) Overview of morphological changes in Parkinson’s disease.Adv. Neurol. 45, 1–18. / Adv. Neurol. by K. Jellinger (1986)
  123. Jellinger K. (1987) The pathology of parkinsonism,Movement Disorders 2 (Marsden C. D. and Fahn St., eds.), pp. 124–165, Butterworth, London. / Movement Disorders 2 by K. Jellinger (1987)
  124. Jellinger K. (1988) The pedunculopontine nucleus in Parkinson’s disease, supranuclear palsy and Alzheimer’s disease.J. Neurol. Neurosurg. Psychiatry 51, 540–544. (10.1136/jnnp.51.4.540) / J. Neurol. Neurosurg. Psychiatry by K. Jellinger (1988)
  125. Jellinger K. (1989) Pathology of Parkinson’s syndrome,Drugs for the Treatment of Pakinson’s Disease (Calne, D. B., ed.), pp. 47–112, Springer, Berlin. (10.1007/978-3-642-73899-9_2) / Drugs for the Treatment of Pakinson’s Disease by K. Jellinger (1989)
  126. Jellinger K. (1990a) Changes in subcortical nuclei in Parkinson’s disease,Function and Dysfunction of the Basal Ganglia (Franks A. J., Ironside J. W., et al., eds.), pp. 69–94, Manchester University Press, Manchester, NY. / Function and Dysfunction of the Basal Ganglia by K. Jellinger (1990)
  127. Jellinger K. (1990b) New developments in the pathology of Parkinson’s diseaseAdv. Neurol. 53, 1–16. / Adv. Neurol. by K. Jellinger (1990)
  128. Jellinger K. (1990c) Morphology of Alzheimer’s disease and related disorders,Alzheimer’s Disease: Epidemiology, Neurochemistry and Clinics (Beckmann H., Maurer M., Riederer P., eds.),Key Topics in Brain Research, pp. 67–77, Springer, Wien. / Alzheimer’s Disease: Epidemiology, Neurochemistry and Clinics by K. Jellinger (1990)
  129. Jellinger K. and Paulus W. (1990) Bedeutung der Nigraveränderungen bei Parkinson-Syndromen,Parkinson-Krankheit und Nigraprozeß, (Fischer, P.-A., ed.), pp. 3–27 Basle: Ed. Roche. / Parkinson-Krankheit und Nigraprozeß by K. Jellinger (1990)
  130. Jenner P. and Marsden C. D. (1990) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): An update on its relevance to the cause and treatment of Parkinson’s disease,Function and Dysfunction of the Basal Ganglia (Franks A. J., et al., eds.), pp. 140–160, Manchester University Press, Manchester, NY. / Function and Dysfunction of the Basal Ganglia by P. Jenner (1990)
  131. Juncos J. L., Hirsch E. C., Malessa S., Duyckaerts C., Hersh L. B., and Agid Y. (1991) Mesencephalic cholinergic nuclei in progressive supranuclear palsy.Neurology 41, 25–30. (10.1212/WNL.41.1.25) / Neurology by J. L. Juncos (1991)
  132. Katzman R., Terry R., DeTeresa R., Brown T., Davies P., Fuld P., Renbing X., and Peck A. (1988) Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous cortical plaques.Ann. Neurol. 23, 138–144. (10.1002/ana.410230206) / Ann. Neurol. by R. Katzman (1988)
  133. Kelly M. and Kowall N. (1989) Corticotropin-releasing factor immunoreactive neurons persist throughout the brain in Alzheimer’s disease.Brain Res. 501, 392. (10.1016/0006-8993(89)90657-4) / Brain Res. by M. Kelly (1989)
  134. Kish S. J., Shannak K., and Hornykiewicz O. (1988) Uneven patterns of dopamine loss in the striatum of patients with Parkinson’s disease.N. Engl. J. Med. 318, 876–880. (10.1056/NEJM198804073181402) / N. Engl. J. Med. by S. J. Kish (1988)
  135. Köhler C., Erikson L. G., Davies S., and Chan-Palay V. (1987) Colocalization of neuropeptide tyrosine and somatostatin immunoreactivity in neurons of individual hippocampal subfields in rat.Neurosci. Lett. 78, 1–6. (10.1016/0304-3940(87)90551-9) / Neurosci. Lett. by C. Köhler (1987)
  136. Konradi C., Svoma E., Jellinger K., Riederer P., Denney R. M. (1988) Topographic immunocytochemical mapping of monoamine oxidase A, monoamine oxidase B and tyrosine hydroxylase in human postmortem brain stem.Neuroscience 26, 791–802. (10.1016/0306-4522(88)90099-1) / Neuroscience by C. Konradi (1988)
  137. Kopin I. J. and Schoenberg D. G. (1988) MPTP in animal models of Parkinson’s disease.Mt. Sinai Med. J. 55, 43–49. / Mt. Sinai Med. J. by I. J. Kopin (1988)
  138. Korczyn A. D. (1989) Autonomic nervous system screening in patients with early Parkinson’s disease,Early Diagnosis and Preventive Therapy in Parkinson Disease (Przuntek H. and Riederer P., eds.), pp. 41–48, Springer, Wien-New York. (10.1007/978-3-7091-8994-8_5) / Early Diagnosis and Preventive Therapy in Parkinson Disease by A. D. Korczyn (1989)
  139. Kowall N. W., and Beal M. F. (1988) Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: Normal anatomy and alterations in Alzheimer’s disease.Ann. Neurol. 23, 105–114. (10.1002/ana.410230202) / Ann. Neurol. by N. W. Kowall (1988)
  140. Kubota Y., Inagaki S., and Kito S. (1986) Innervation of substance P neurons by catecholaminergic terminals in the neostriatum.Brain Res. 375, 163–167. (10.1016/0006-8993(86)90969-8) / Brain Res. by Y. Kubota (1986)
  141. Langston J. W. and Irwin I. (1989) Pyridine toxins,Drugs for the treatment of Parkinson’s Disease (Calne D. B., ed.), pp. 205–226., Springer, Berlin-New York. (10.1007/978-3-642-73899-9_7) / Drugs for the treatment of Parkinson’s Disease by J. W. Langston (1989)
  142. Lewy F. H. (1913) Zur pathologischen Anatomie der Paralysis agitans.Dtsch. Z. Nervenheilk. 50, 50–55. / Dtsch. Z. Nervenheilk. by F. H. Lewy (1913)
  143. Li S. J., Sivam S. P., McGinty J. F., Huang Y. S. and Hong J. S. (1987) Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway.J. Pharmacol. Exp. Ther. 243, 792–798. (10.1016/S0022-3565(25)11003-3) / J. Pharmacol. Exp. Ther. by S. J. Li (1987)
  144. Llorens-Cortes C., Javoy-Agid F., Agid Y, Taquet H., and Schwartz J. C. (1984) Enkephalinergic markers in substantia nigra and caudate nucleus from parkinsonian subjects.J Neurochem. 43, 874–877. (10.1111/j.1471-4159.1984.tb12812.x) / J Neurochem. by C. Llorens-Cortes (1984)
  145. Loughlin S. E., Foote S. L., and Bloom F. E. (1986) Efferent projections of nucleus locus coeruleus: Topographic organization of cells of origin demonstrated by three-dimensional reconstruction.Neuroscience 18, 291–306. (10.1016/0306-4522(86)90155-7) / Neuroscience by S. E. Loughlin (1986)
  146. Loew-Hummel P., Gertz H.-J. Ferszt R., and Cervos-Navarro J. (1989) The basal nucleus of Meynert revisited.Arch. Gerontol. Geriatr. 8, 21–27. (10.1016/0167-4943(89)90066-6) / Arch. Gerontol. Geriatr. by P. Loew-Hummel (1989)
  147. McGeer E. G., and McGeer P. L. (1989) Biochemical neuroanatomy of the basal ganglia,Drugs for the Treatment of Parkinson’s Disease (Calne D. B., ed.), pp. 112–148,Handbook of Experimental Pharmacology vol. 88, Springer, Wien-New York. / Drugs for the Treatment of Parkinson’s Disease by E. G. McGeer (1989)
  148. McGeer P. L., McGeer E. G., and Suzuki J. (1984) Aging, Alzheimer’s disease, and the cholinergic system in the basal forebrain.Neurology 34, 741–745. (10.1212/WNL.34.6.741) / Neurology by P. L. McGeer (1984)
  149. Malessa S., Hirsch E. C., Cerver P., Duyckaerts C., and Agid Y. (1990) Catecholaminergic systems in the medulla oblongata in Parkinsonian syndromes. A quantitative immunohistochemical study in Parkinson’s disease, progressive supranuclear palsy, and striatonigral degeneration.Neurology 40, 1739–1742. (10.1212/WNL.40.11.1739) / Neurology by S. Malessa (1990)
  150. Maloteaux J. M., Laterre E. C., Ladurot P. M., Javoy-Agid F., and Agid Y. (1988) Decrease of serotonin-R-2 receptors in temporal cortex of patients with Parkinson’s disease and progressive supranuclear palsy.Movement Disord. 3, 255–262. (10.1002/mds.870030310) / Movement Disord. by J. M. Maloteaux (1988)
  151. Mann D. M. A. and Yates P. O. (1983) Pathological basis for neurotransmitter changes in Parkinson’s disease.Neuropathol Appl. Neurobiol. 9, 3–19. (10.1111/j.1365-2990.1983.tb00320.x) / Neuropathol Appl. Neurobiol. by D. M. A. Mann (1983)
  152. Mann D. M. A. and Yates P. O. (1986) Neurotransmitter deficits in Alzheimer’s disease and other dementing disorders.Hum. Neurobiol. 5, 147–156. / Hum. Neurobiol. by D. M. A. Mann (1986)
  153. Mann D. M. A., Yates P. O., and Hawkes J. (1983) The pathology of the human locus coeruleus.Clin. Neuropathol. 2, 1–7. / Clin. Neuropathol. by D. M. A. Mann (1983)
  154. Mann D. M. A., Yates P. O., and Marcyniuk B. (1984) Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer’s disease and their relationship to the accumulation of lipofuscin pigment.Mech. Ageing Dev. 25, 189–204. (10.1016/0047-6374(84)90140-4) / Mech. Ageing Dev. by D. M. A. Mann (1984)
  155. Mann D. M. A., Yates P. O., and Marcyniuk B. (1985a) Correlation between senile plaques and neurofibrillary tangle counts in the cerebral cortex and neuron al counts in cortex and subcortical structures in Alzheimer’s disease.Neurosci. Lett. 56, 51–55. (10.1016/0304-3940(85)90439-2) / Neurosci. Lett. by D. M. A. Mann (1985)
  156. Mann D. M. A., Yates P. O., and Marcyniuk B. (1985b) Changes in Alzheimer’s disease in the magnocellular neurons of the supraoptic and paraventricular nuclei and their relationship to the noradrenergic deficit.Clin. Neuropathol. 4, 127. / Clin. Neuropathol. by D. M. A. Mann (1985)
  157. Mann D. M. A., Yates P. O., and Marcyniuk B. (1987) Dopaminergic systems in Alzheimer’s disease and Down’s syndrome at middle age.J. Neurol. Neurosurg. Psychiatry 50, 341–344. (10.1136/jnnp.50.3.341) / J. Neurol. Neurosurg. Psychiatry by D. M. A. Mann (1987)
  158. Marcyniuk B., Mann D. M. A., and Yates P. O. (1986) Loss of nerve cells from locus coeruleus in Alzheimer’s disease is topographically arranged.Neurosci. Lett. 64, 247–252. (10.1016/0304-3940(86)90336-8) / Neurosci. Lett. by B. Marcyniuk (1986)
  159. Marcyniuk B., Mann D. M. A., and Yates P. O. (1989) The topography of nerve cell loss from the locus coeruleus in elderly persons.Neurobiol Aging 10, 5–9. (10.1016/S0197-4580(89)80004-1) / Neurobiol Aging by B. Marcyniuk (1989)
  160. Masullo C., Pocchiari M., Mariotti P., Macchi G., Garruto R. M., Gibbs C. J. Jr., et al. (1989) The nucleus basalis of Menyert in Parkinson-dementia of Guam: A morphometric study.Neuropathol. Appl. Neurobiol. 15, 193–206. (10.1111/j.1365-2990.1989.tb01222.x) / Neuropathol. Appl. Neurobiol. by C. Masullo (1989)
  161. Matzuk M. M. and Saper C. B. (1985) Preservation of hypothalamic dopaminergic neurons in Parkinson’s disease.Ann. Neurol. 18, 552–555. (10.1002/ana.410180507) / Ann. Neurol. by M. M. Matzuk (1985)
  162. Mauborgne A., Javoy-Agid F., Legrand J. C., Agid Y., and Cesselin F. (1983) Decrease of substance P-like immunoreactivity in the substantia nigra and palidum of parkinsonian brains.Brain Res. 268, 167–170. (10.1016/0006-8993(83)90403-1) / Brain Res. by A. Mauborgne (1983)
  163. Mayeux R. (1990) The “serotonin hypothesis” for depression in Parkinson’s disease.Adv. Neurol. 53, 163–166. / Adv. Neurol. by R. Mayeux (1990)
  164. Meltzer H. (1989) Serotonergic dysfunction in depression.Br. J. Psychiatry 155, 25–31. (10.1192/S0007125000291733) / Br. J. Psychiatry by H. Meltzer (1989)
  165. Mesulam M. M., and Geula C. (1988) Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase.J. Comp. Neurol. 275, 216–260. (10.1002/cne.902750205) / J. Comp. Neurol. by M. M. Mesulam (1988)
  166. Mesulam M. M and Mufson E. J. (1984) Neuronal inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey.Brain 107, 253–274. (10.1093/brain/107.1.253) / Brain by M. M Mesulam (1984)
  167. Mitchell I. J., Aambrook M. A., Jackson A., Clarke C. E., Robertson R. G., Boyce S., and Crossman A. R. (1990) Basal ganglia function in experimental movement disorders,Function and Dysfunction in the Basal Ganglia (Franks A. J. et al., eds.), pp. 94–109, Manchester University Press, Manchester, NY. / Function and Dysfunction in the Basal Ganglia by I. J. Mitchell (1990)
  168. Mizutani T., Aki M., Shiozawa R., Tanabe H. Uchigata M. Oda M., Endo Y., and Hara M. (1991) Clinico-pathologic study of dementia in Parkinson’s disease with special reference to degeneration of the locus ceruleus.Acta Neuropathol. (Berl.) 81, in press. (10.1159/000107210)
  169. Moossy J., Zubenko G. B., Martinez J., and Rao G. (1988) Bilateral symmetry of morphologic lesions in Alzheimer’s disease.Arch. Neurol. 45, 251–254. (10.1001/archneur.1988.00520270025015) / Arch. Neurol. by J. Moossy (1988)
  170. Mufson E. J., Mash D., and Hersh L. B. (1988) Neurofibrillary tangles in cholinergic pedunculopontine nucleus in Alzheimer’s disease.Ann. Neurol. 24, 623–629. (10.1002/ana.410240506) / Ann. Neurol. by E. J. Mufson (1988)
  171. Mufson E. J., Presley L. N., and Kordower J. H. (1991) Nerve growth factor immunoreactivity with the nucleus basalis (Hc 4) in Parkinson disease. Reduced cell numbers and co-localization with cholinergic neurons.Brain Res. 539, 19–30. (10.1016/0006-8993(91)90682-L) / Brain Res. by E. J. Mufson (1991)
  172. Mulligan K. A. and Tork I. (1988) Serotonergic innervation of the cat cerebral cortex.J. Comp. Neurol. 270, 86–110. (10.1002/cne.902700108) / J. Comp. Neurol. by K. A. Mulligan (1988)
  173. Nagatsu T. (1990) Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP treated mice.Adv. Neurol. 53, 207–214. / Adv. Neurol. by T. Nagatsu (1990)
  174. Nakano I. and Hirano A. (1984) Neuron loss in the nucleus basalis of Meynert in Parkinson-dementia complex of Guam.Ann. Neurol. 13, 87–91. (10.1002/ana.410130118) / Ann. Neurol. by I. Nakano (1984)
  175. Nakashima S. and Ikuta F. (1984) Tyrosine hydroxylase proteins in Lewy bodies of parkinsonism and senile brain.J. Neurol. Sci. 66, 91–96. (10.1016/0022-510X(84)90144-8) / J. Neurol. Sci. by S. Nakashima (1984)
  176. Nemeroff C. B., Kizer J. S., Reynolds G. P., and Bisette G. (1989) Neuropeptides in Alzheimer’s disease: A postmortem study.Regul. Pept. 25, 123–130. (10.1016/0167-0115(89)90254-1) / Regul. Pept. by C. B. Nemeroff (1989)
  177. Nieuwenhuys R., Voogd J., and Van Huijzen C. (1988)The Human Central Nervous System. A Synopsis and Atlas 3rd Ed., (Springer, Berlin). (10.1007/978-3-662-10343-2) / The Human Central Nervous System. A Synopsis and Atlas by R. Nieuwenhuys (1988)
  178. Olszewski J. and Baxter D. (1982)Cytoarchitecture of the Human Brain Stem 2nd Ed. (Karger, Basel, New York). / Cytoarchitecture of the Human Brain Stem by J. Olszewski (1982)
  179. Palmer A. M., Francis P. T., Bowen D. M., Benton J. S., Neary D., Mann D. M., and Swanson J. S. (1987) Catecholaminergic neurons assessed ante-mortem in Alzheimer’s disease.Brain Res. 414, 365–375. (10.1016/0006-8993(87)90018-7) / Brain Res. by A. M. Palmer (1987)
  180. Paulus W. and Jellinger K. (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease.J. Neuropathol Exp. Neurol., in press. (10.1097/00005072-199111000-00006)
  181. Pearson R. C. A., and Powell T. P. S. (1987) Anterograde vs retrograde degeneration of the nucleus basalis medialis in Alzheimer’s disease.J. Neural Transm. (Suppl.) 24, 139–146. / J. Neural Transm. (Suppl.) by R. C. A. Pearson (1987)
  182. Pearson R. C. A., Sofroniew M. V., Cuello A. C., Powell T. P., Eckenstein, F., Esiri M. M., and Wilcock G. K. (1983) Persistence of cholinergic neurons in the basal nucleus of a brain with senile dementia of the Alzheimer’s type.Brain Res. 289, 375–379. (10.1016/0006-8993(83)90046-X) / Brain Res. by R. C. A. Pearson (1983)
  183. Perry E. K., Smith C. J., Court J. A., and Perry R. H. (1990a) Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types.J Neural Transm. (P-D Sect.) 2, 149–158. (10.1007/BF02257646) / J Neural Transm. (P-D Sect.) by E. K. Perry (1990)
  184. Perry E. K., Smith C. J., Perry R. H., Johnson M., and Fairbairn A. F. (1989) Nicotinic (3H-nicotine) receptor binding in human brain: Characterization and involvement in cholinergic neuropathology.Neurosci. Res. Commun. 5, 117–124. / Neurosci. Res. Commun. by E. K. Perry (1989)
  185. Perry E. K., Curtis M., Dick D. J., Atack J. H, Bloxham C. A., Blessed G., Fairbairn A., Tomlinson B. E., and Perry R. H. (1985) Cholinergic correlates of cognitive impairment in Parkinson’s disease: Comparison with Alzheimer’s disease.J. Neurol. Neurosurg. Psychiatry 48, 413–421. (10.1136/jnnp.48.5.413) / J. Neurol. Neurosurg. Psychiatry by E. K. Perry (1985)
  186. Perry E. K., Tomlinson B. E., Blessed G., Perry R. H., Cross A. J., and Crow T. J. (1981) Neuropathological and biochemical observations on the noradrenergic system in Alzheimer’s disease.J. Neurol. Sci. 51, 279–287. (10.1016/0022-510X(81)90106-4) / J. Neurol. Sci. by E. K. Perry (1981)
  187. Perry R. H. (1986) Alzheimer’s disease: Recent advances in neuropathology.Br. Med. Bull. 42, 45–50. / Br. Med. Bull. by R. H. Perry (1986)
  188. Perry R. H., Irving D., Blessed G., Fairbairn A. F., and Perry E. K. (1990b) Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly.J. Neurol. Sci. 95, 119–139. (10.1016/0022-510X(90)90236-G) / J. Neurol. Sci. by R. H. Perry (1990)
  189. Perry R. H., Tomlinson B. E., Candy J. M., Blessed G., Foster J. F., Bloxham C. A., and Perry E. R. (1983) Cortical cholinergic deficit in mentally impaired Parkinsonian patients.Lancet 2, 311–315. / Lancet by R. H. Perry (1983)
  190. Perry R. H., Perry E. K., Smith C. J., Xuereb J. H., Irving D., Whitford C. A. Candy J. M., and Cross A. J. (1987) Cortical neuropathological and neurochemical substrates of Alzheimer’s and Parkinson’s disease.J. Neural Transm. (Suppl.) 24, 131. / J. Neural Transm. (Suppl.) by R. H. Perry (1987)
  191. Probst A., Cortex R., Ulrich J., and Palacios J. M. (1988) Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer’s disease: An autoradiographic study.Brain Res. 450, 190–201. (10.1016/0006-8993(88)91558-2) / Brain Res. by A. Probst (1988)
  192. Quirion R., Martel J. C., Robitaille Y. Etienne P., Wood P., Nair N. P. V. and Gauthier S. (1986) Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type.Can. J. Neurol. Sci. 13, 503–510. (10.1017/S0317167100037215) / Can. J. Neurol. Sci. by R. Quirion (1986)
  193. Ransmayer G., Cervera P., Hirsch E. Ruberg M., Hersh L. B., Duyckaerts C., Hauw J. J., Deluneau F., and Agid Y. (1989) Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer’s disease.Neuroscience 32, 701–714. (10.1016/0306-4522(89)90291-1) / Neuroscience by G. Ransmayer (1989)
  194. Rascol O., Clanet M., Motastruc J. L., Simonetta M., Soulier-Esteve M. J., Doyon B., and Rascol A. (1989) Abnormal ocular movements in Parkinson’s disease.Brain 112, 1193–1214. (10.1093/brain/112.5.1193) / Brain by O. Rascol (1989)
  195. Reid M. S., Herrera-Marschitz M., Hökfelt T., Lindefors N., Persson H., and Ungerstedt U. (1990) Striatonigral GABA dynorphin, substance P and neurokinin-A modulation of nigrostriatal release. Evidence for direct regulatory mechanisms.Exp. Brain Res. 82, 293–304. / Exp. Brain Res. by M. S. Reid (1990)
  196. Reinikainen R., Paljärvi L., and Huusekonnen M. (1988b) A postmortem study of noradrenergic, serotonergic and GABAergic neurones in Alzheimer’s disease.J. Neurol. Sci. 84, 101–115. (10.1016/0022-510X(88)90179-7) / J. Neurol. Sci. by R. Reinikainen (1988)
  197. Reinikainen K. J., Riekkinen P. J., and Paljärvi L (1988a) Cholinergic deficit in Alzheimer’s disease: A study based on CSF and autopsy data.Neurochem. Res. 13, 135–146. (10.1007/BF00973325) / Neurochem. Res. by K. J. Reinikainen (1988)
  198. Ricaurte G. A., Irwin I., Forno L. S., DeLanney L. E., Langston E. B., and Langston J. W. (1987) Aging and MPTP-induced degeneration of dopaminergic neurons in the substantia nigra.Brain Res. 403, 43–51. (10.1016/0006-8993(87)90120-X) / Brain Res. by G. A. Ricaurte (1987)
  199. Riederer P., Rausch W. D., Birkmayer W., Jellinger K., and Seeman D. (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies.J. Neural Transm. (Suppl.) 14, 121–133. / J. Neural Transm. (Suppl.) by P. Riederer (1978)
  200. Riederer P., Sofic E., Konradi C., Kornhuber J., Beckmann H., Dietl M., Moll G., and Hebenstreit G. (1990) The role of dopamine in the control of neurobiological functions,The Role of Brain Dopamine (Flückinger E., Müller E. E., and Thorner M. O., eds.), pp. 1–17, Springer, Berlin. / The Role of Brain Dopamine by P. Riederer (1990)
  201. Rinne J. O., Paljärvi L., and Rinne U. K. (1987) Neuronal size and density in the nucleus basalis Meynert in Alzheimer’s disease.J. Neurol. Sci. 79, 67–76. (10.1016/0022-510X(87)90260-7) / J. Neurol. Sci. by J. O. Rinne (1987)
  202. Rinne J. O., Lönnberg P., Marjamäki P., and Rinne U. K. (1989b) Brain muscarinic receptor subtypes are differentially affected in Alzheimer’s disease and Parkinson’s disease.Brain Res. 483, 402–406. (10.1016/0006-8993(89)90188-1) / Brain Res. by J. O. Rinne (1989)
  203. Rinne J. O., Rummukainien J., Paljärvi L., and Rinne U. K. (1989a) Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra.Ann. Neurol. 26, 47–50. (10.1002/ana.410260107) / Ann. Neurol. by J. O. Rinne (1989)
  204. Rinne U. K., Rinne J. K., Rinne J. O., Laakso K., Tenovuo L., Lönnberg P., Koskinen V. (1983) Brain enkephalin receptors in Parkinson’s disease.J. Neural Transm. (Suppl.) 19, 163–171. / J. Neural Transm. (Suppl.) by U. K. Rinne (1983)
  205. Rogers J. D., Brogan D., and Mirra S. S. (1985) The nucleus basalis Meynert in neurological disease: A quantitative morphological study.Ann. Neurol. 17, 163. (10.1002/ana.410170210) / Ann. Neurol. by J. D. Rogers (1985)
  206. Rossor M. N., Iversen L. I., and Reynolds G. P. (1984) Neurochemical characteristics of early and late onset types of Alzheimer’s disease.Br. Med. J. 288, 961–964. (10.1136/bmj.288.6422.961) / Br. Med. J. by M. N. Rossor (1984)
  207. Ruberg M. and Agid Y. (1988) Dementia in Parkinson’s disease,Handbook of Psychopharmacology, vol. 20 (Iversen L., et al., eds.), Plenum, New York. / Handbook of Psychopharmacology by M. Ruberg (1988)
  208. Ruberg M., Javoy-Agid F., Hirsch E., Scatton B., LHeureux R., Hauw J. J., Duyckaerts C., Gray F., Morel-Maroger A., and Rascol A. (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy.Ann. Neurol. 18, 523–529. (10.1002/ana.410180503) / Ann. Neurol. by M. Ruberg (1985)
  209. Sadoul J. L., Checler F., Kitabki P., Rostene W., Javoy-Agid F., and Vincent J. P. (1984) Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects.Biochem. Biophys. Res. Commun. 125, 395–404. (10.1016/S0006-291X(84)80381-2) / Biochem. Biophys. Res. Commun. by J. L. Sadoul (1984)
  210. Saper C. B., German D. C., and White C. L. (1985) Neuronal pathology in the nucleus basalis of Meynert and associated cell groups in senile dementia of the Alzheimer’s type. Possible role in cell loss.Neurology 35, 1089–1095. (10.1212/WNL.35.8.1089) / Neurology by C. B. Saper (1985)
  211. Scarnati E., Gasbarri A., Campana E., and Pacitti C. (1987) The organization of the nucleus tegmenti pedunculopontine neurons projecting to basal ganglia and thalamus.Neurosci. Lett. 79, 11–16. (10.1016/0304-3940(87)90664-1) / Neurosci. Lett. by E. Scarnati (1987)
  212. Scatton B., Dennis T., L’Heureux R., Montofort J., Duyckaerts C., and Javoy-Agid F. (1986) Degeneration of noradrenergic and serotonergic but not dopaminergic neurons in lumbar spinal cord of parkinsonian patients.Brain Res. 380, 181–185. (10.1016/0006-8993(86)91446-0) / Brain Res. by B. Scatton (1986)
  213. Schneider J. S., Yuwiler A., and Markham C. H. (1987) Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.Brain Res. 411, 144–150. (10.1016/0006-8993(87)90691-3) / Brain Res. by J. S. Schneider (1987)
  214. Shin R.-W., Kitamoto T., and Tateishi J. (1991) Modified tau is present in younger nondemented persons: A study of subcortical nuclei in Alzheimer’s disease and progressive supranuclear palsy.Acta Neuropathol. (Berl.) 81, in press. (10.1007/BF00310132)
  215. Sirvio J., Rinne J. O., Valjakka A., Rinne U. K., Riekkinen P. J., and Paljärvi L. (1989) Different forms of brain acetylcholinesterase and muscarinic binding in Parkinson’s disease.J. Neurol. Sci. 90, 23–32. (10.1016/0022-510X(89)90042-7) / J. Neurol. Sci. by J. Sirvio (1989)
  216. Sofic E., Moll G., Riederer P., Jellinger K., and Gabriel E. (1988) Monoaminerge Läsion bei seniler Demenz vom Alzheimer-Typ (SDAT).Biologische Psychiatrie. Synopsis 1986/87 (Beckmann H., and Laux G., eds.), pp. 151–157, Springer, Berlin. (10.1007/978-3-642-72922-5_29) / Biologische Psychiatrie. Synopsis 1986/87 by E. Sofic (1988)
  217. Sparks D. L., DeKosky S. T., and Markesberry W. (1988) Alzheimer’s disease. Aminergic-cholinergic alterations in hypothalamus.Arch. Neurol. 45, 994–999. (10.1001/archneur.1988.00520330084014) / Arch. Neurol. by D. L. Sparks (1988)
  218. Steinbush H. W. M. (1984) Serotonin-immunoreactive neurons and their projections in the CNS,Handbook of Chemical Neuroanatomy, vol. 3: Classical Transmitters and Transmitter Receptors in CNS, Part II (Björklund A., Hökfelt T., and Kuhar M. J., eds.), pp. 68–125, Elsevier, Amsterdam-New York. / Handbook of Chemical Neuroanatomy, vol. 3: Classical Transmitters and Transmitter Receptors in CNS, Part II by H. W. M. Steinbush (1984)
  219. Steriade M. and Biesold D. (1990)Brain Cholinergic Systems, Oxford University Press. (10.1093/oso/9780198542667.001.0001)
  220. Studler J. M. and Javoy-Agid F. (1985) Cholecystokinin octapeptide immunoreactivity distribution in human brain.Ann. NY Acad. Sci. 448, 656–659. (10.1111/j.1749-6632.1985.tb29979.x) / Ann. NY Acad. Sci. by J. M. Studler (1985)
  221. Swaab D. F., Fliers E., and Goudsmit E. (1986) Differential cell loss in (peptide) neurons in the anterior hypothalamus with aging and Alzheimer’s disease,Neurology (Poeck K., Freund H. J., Gänshirt H., eds.), p. 119–125, Springer. (10.1007/978-3-642-70007-1_14)
  222. Swanson L. W. (1982) Normal hippocampal circuitry.Neurosci. Res. Progr. Bull. 9, 624–637. / Neurosci. Res. Progr. Bull. by L. W. Swanson (1982)
  223. Tabaton M., Schenone A., Romagnoli P., and Mancardi G. L. (1985) A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer’s disease.Acta Neuropathol. (Berl.) 68, 218–223. (10.1007/BF00690198) / Acta Neuropathol. (Berl.) by M. Tabaton (1985)
  224. Tagliavini F. and Pilleri G. (1984) The basal nucleus of Meynert in cerebral aging and degenerative dementias,Brain Pathology (Tagliavini F. and Pilleri G., eds.), The basal nucleus of Meynert in cerebral aging and degenerative dementias,Brain Pathology (Tagliavini F. and Pilleri G., eds.), vol. 1, pp. 181–218. Bern. (10.1016/0022-510X(83)90203-4)
  225. Tagliavini F., Pilleri G., Bouraas C., and Constantinidis J. (1984) The nucleus basalis of Meynert in cerebral aging and degenerative dementias,Brain Pathology (Tagliavini F., and Pilleri G., eds.) pp. 181–218. Bern.
  226. Taquet H., Javoy-Agid F., Giraud P., Legrand J. D., Agid Y., and Cesselin F. (1985) Dynorphin levels in parkinsonian patients.Brain Res. 341, 390–392. (10.1016/0006-8993(85)91081-9) / Brain Res. by H. Taquet (1985)
  227. Taquet H., Nomoto M., Rose S., Jenner P., Javoy-Agid F., Mauborgne A., Benoliel J. J., Marsden C. D., Legrand J. C., Agid Y., Hamon M., and Cesselin F. (1988) Levels of MET-Enkephalin, LEU-Enkephalin, Substance P and Cholecystokinin in the Brain of the Common Marmoset Following Long Term 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Treatment.Neuropeptides 12, 105–110. (10.1016/0143-4179(88)90039-X) / Neuropeptides by H. Taquet (1988)
  228. Tenovuo O., Rinne J. K., and Viljanen M. K. (1984) Substance P immunoreactivity in post-mortem parkinsonian brain.Brain Res. 303, 113–116. (10.1016/0006-8993(84)90217-8) / Brain Res. by O. Tenovuo (1984)
  229. Tenovuo O., Kolhinen A., Laihinen A., and Rinne U. K. (1990) Brain substance P receptors in Parkinson’s disease.Adv. Neurol. 53, 145–148. / Adv. Neurol. by O. Tenovuo (1990)
  230. Terry R. D., Masliah E., Salmon D., and DeTeresa H. (1990) Structure-function correlations in Alzheimer’s disease (abstract).J. Neuropathol. Exp. Neurol. 49, 318. (10.1097/00005072-199005000-00176) / J. Neuropathol. Exp. Neurol. by R. D. Terry (1990)
  231. Tomlinson B. E. (1989) The neuropathology of Alzheimer’s disease—issues in need of resolution.Neuropathol. Appl. Neurobiol. 15, 491–512. (10.1111/j.1365-2990.1989.tb01250.x) / Neuropathol. Appl. Neurobiol. by B. E. Tomlinson (1989)
  232. Tomlinson B. E., Irving D., and Blessed G. (1981) Cell loss in the locus coeruleus in senile dementia of the Alzheimer type.J. Neurol. Sci. 49, 419–428. (10.1016/0022-510X(81)90031-9) / J. Neurol. Sci. by B. E. Tomlinson (1981)
  233. Tomonoga M. (1983) Neuropathology of the locus coeruleus: A semiquantitative study.J. Neurol. 230, 231–240. (10.1007/BF00313699) / J. Neurol. by M. Tomonoga (1983)
  234. Torack R. M. and Morris J. C. (1986) Mesocorticolimbical dementia.Arch. Neurol. 43, 1074–1078. (10.1001/archneur.1986.00520100078018) / Arch. Neurol. by R. M. Torack (1986)
  235. Torack R. M. and Morris J. C. (1988) The association of ventral tegmental area histopathology with adult dementia.Arch. Neurol. 45, 497–501. (10.1001/archneur.1988.00520290025008) / Arch. Neurol. by R. M. Torack (1988)
  236. Uhl G. R., Hedreen J. C., and Price D. L. (1985) Parkinson’s disease: Loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions.Neurology 35, 1215–1218. (10.1212/WNL.35.8.1215) / Neurology by G. R. Uhl (1985)
  237. Uhl G. R., McKinney M., Hedreen J. C., White C. L., Coyle J. T., Whitehouse P. J., and Price D. L. (1982) Dementia pugilistica: Loss of basal forebrain cholinergic neurons and cortical cholinergic markers.Ann. Neurol. 12, 99–102. / Ann. Neurol. by G. R. Uhl (1982)
  238. Ulfig N. (1989) Altered lipofuscin pigmentation in the basal nucleus (Meynert) in Parkinson’s disease.Neurosci. Res. 6, 456–462. (10.1016/0168-0102(89)90007-2) / Neurosci. Res. by N. Ulfig (1989)
  239. Verity M. A. Roitberg B. and Kepes J. J. (1990) Mesolimbicocortical dementia: Clinico-pathological studies on two cases.J. Neurol. Neurosurg. Psychiatry 53, 492–495. (10.1136/jnnp.53.6.492) / J. Neurol. Neurosurg. Psychiatry by M. A. Verity (1990)
  240. Vijayshankar N. and Brody H. (1979) A quantitative study of pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging.J. Neuropathol. Exp. Neurol. 38, 490–497. (10.1097/00005072-197909000-00004) / J. Neuropathol. Exp. Neurol. by N. Vijayshankar (1979)
  241. Vogels O. J. M., Broere C. A. J., and Nieuwenhuys R. (1990a) Neuronal hypertrophy in the human supraoptic and paraventricular nucleus in aging and Alzheimer’s disease.Neurosci. Lett. 109, 62–67. (10.1016/0304-3940(90)90538-K) / Neurosci. Lett. by O. J. M. Vogels (1990)
  242. Vogels O. J. M., Broere C. A. J., Ter Laak H. J., Ten Donkellar H. J., Nieuwenhuys R. and Schulte B. M. (1990b) Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer’s disease.Neurobiol. Aging 11, 3–13. (10.1016/0197-4580(90)90056-6) / Neurobiol. Aging by O. J. M. Vogels (1990)
  243. Wakabayashi K., Takahashi H., Takeda S., Ohama E., and Ikuta F. (1988) Parkinson’s disease: The presence of Lewy bodies in Auerbach’s and Meissner’s plexuses.Acta Neuropathol. (Berl.) 76, 217–221. (10.1007/BF00687767) / Acta Neuropathol. (Berl.) by K. Wakabayashi (1988)
  244. Waters C. M., Peck P., Rossor M., Reynolds G. P., and Hunt S. P. (1988) Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson’s disease and Huntington’s chora.Neuroscience 25, 419–438. (10.1016/0306-4522(88)90249-7) / Neuroscience by C. M. Waters (1988)
  245. Westlund K. N., Denney R. M., Kochersberger L. M., Rose R. M., and Abell C. W. (1985) Distinct monoamine oxidase A and B populations in primate brain.Science 230, 181–183. (10.1126/science.3875898) / Science by K. N. Westlund (1985)
  246. Westlund K. N., Denney R. M., Rose R., and Abell C. M. (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem.Neuroscience 25, 439–456. (10.1016/0306-4522(88)90250-3) / Neuroscience by K. N. Westlund (1988)
  247. White O. B., Saint-Cyr J. A., Tomlinson R. D., and Sharpe J. A. (1983) Ocular motor deficits in Parkinson’s disease. I and II.Brain 106, 555–587. (10.1093/brain/106.3.555) / Brain by O. B. White (1983)
  248. Whitehouse P. J., Hedreen J. C., White C. L., and Price D. L. (1983) Basal forebrain neurons in the dementia of Parkinson’s disease.Ann. Neurol. 13, 243–248. (10.1002/ana.410130304) / Ann. Neurol. by P. J. Whitehouse (1983)
  249. Whitehouse P. J., Vale W. W., Zweig R. M., Singer H. S., Mayeux R., Kuhar M. J., Price D. L., and DeSouza E. B. (1987) Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer’s disease, Parkinson’s disease and progressive supranuclear palsy.Neurology 37, 905–909. (10.1212/WNL.37.6.905) / Neurology by P. J. Whitehouse (1987)
  250. Whitehouse P. J., Martino A. M., Wagster M. V., Price M. L., Mayeux R., Atack J. R., and Kellar K. J. (1988) Reductions in [3H]nicotinic acetylcholine binding in Alzheimer’s disease and Parkinson’s disease: An autoradiographic study.Neurology 38, 720–723. (10.1212/WNL.38.5.720) / Neurology by P. J. Whitehouse (1988)
  251. Whitford C., Candy J., Edwardson J., and Perry J. (1988) Cortical somatostatinergic system not affected in Alzheimer’s and Parkinson’s diseases.J. Neurol. Sci. 86, 13–18. (10.1016/0022-510X(88)90003-2) / J. Neurol. Sci. by C. Whitford (1988)
  252. Wilcock G. K., Esiri M. M., Bowen D., and Hughes A. O. (1988) The differential involvement of subcortical nuclei in senile dementia of the Alzheimer type.J. Neurol. Neurosurg. Psychiatry 51, 842–849. (10.1136/jnnp.51.6.842) / J. Neurol. Neurosurg. Psychiatry by G. K. Wilcock (1988)
  253. Xuereb J. H., Perry E. K., Candy J. M., Bonham J. R., Perry R. H., and Marschall E. (1990) Parameters of cholinergic neurotransmission in the thalamus in Parkinson’s disease and Alzheimer’s disease.J. Neurol. Sci. 99, 185–197. (10.1016/0022-510X(90)90155-G) / J. Neurol. Sci. by J. H. Xuereb (1990)
  254. Yamada T., McGeer P. L., Baimbridge K. G., and McGeer E. G. (1990) Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbinding D 28K.Brain Res. 526, 303–307. (10.1016/0006-8993(90)91236-A) / Brain Res. by T. Yamada (1990)
  255. Yamamoto T. and Hirano A. (1985) Nucleus raphe dorsalis in Parkinson’s dementia complex of Guam.Acta Neuropathol. (Berl.) 67, 296–299. (10.1007/BF00687815) / Acta Neuropathol. (Berl.) by T. Yamamoto (1985)
  256. Yates C. M., Fink G. M., Bennie J. G., Gordon A., Simpson J., and Eskay R. L. (1984) Neurotensin immunoreactivity in post-mortem brain is increased in Down’s syndrome but not in Alzheimer-type dementia.J. Neurol. Sci. 67, 327–335. (10.1016/0022-510X(85)90157-1) / J. Neurol. Sci. by C. M. Yates (1984)
  257. Zech M. and Bogerts B. (1985) Methionine, enkephalin and substance P in the basal ganglia of schizophrenics: A quantitative immunohistochemical comparison with Huntington and Parkinson patients.Acta Neuropathol. (Berl.) 68, 32–38. (10.1007/BF00688953) / Acta Neuropathol. (Berl.) by M. Zech (1985)
  258. Zubenko G. S., Moossy J., and Kopp U. (1990) Neurochemical correlates of major depression in primary dementia.Arch. Neurol. 47, 209–214. (10.1001/archneur.1990.00530020117023) / Arch. Neurol. by G. S. Zubenko (1990)
  259. Zubenko G. S., Moossy J., Hanin I., Martinez A. J., Rao G. R., and Kopp G. R. (1988) Bilateral symmetry of cholinergic deficits in Alzheimer’s disease.Arch. Neurol. 45, 255–259. (10.1001/archneur.1988.00520270029016) / Arch. Neurol. by G. S. Zubenko (1988)
  260. Zweig R. M., Jankel W. R., Hedreen J. C., Mayeux R., and Price D. L. (1989a) The pedunculopontine nucleus in Parkinson’s disease.Ann. Neurol. 26, 41–46. (10.1002/ana.410260106) / Ann. Neurol. by R. M. Zweig (1989)
  261. Zweig R. M., Rose C. A., Hedreen J. C., Steele C., Cardillo J. E., Whitehouse P. J., Folstein M. F., and Price D. L. (1988a) The neuropathology of aminergic nuclei in Alzheimer’s disease.Ann. Neurol. 24, 233–242. (10.1002/ana.410240210) / Ann. Neurol. by R. M. Zweig (1988)
  262. Zweig R. M., Ross C. A., Peyser C., Cardillo J. E., Coehn M., Folstein S., and Price D. L. (1988b) The locus ceruleus and dementia in Parkinson’s disease and Huntington’s disease.Ann. Neurol. 24, 133. (10.1002/ana.410240210) / Ann. Neurol. by R. M. Zweig (1988)
  263. Zweig R. M., Ross C. A., Hedreen J. C., Steele C., Cardillo J. E., Whitehouse P. J., Folstein M. F., and Price D. L. (1989b) Neuropathology of aminergic nuclei in Alzheimer’s disease,Alzheimer’s disease and related disorders (Iqbal K., and Wisniewski H. M., eds.) pp. 353–365, A. R. Liss, New York. / Alzheimer’s disease and related disorders by R. M. Zweig (1989)
Dates
Type When
Created 16 years ago (Aug. 20, 2009, 7:54 p.m.)
Deposited 6 months, 2 weeks ago (Feb. 11, 2025, 3:22 p.m.)
Indexed 2 weeks, 5 days ago (Aug. 6, 2025, 8:59 a.m.)
Issued 34 years, 2 months ago (June 1, 1991)
Published 34 years, 2 months ago (June 1, 1991)
Published Print 34 years, 2 months ago (June 1, 1991)
Funders 0

None

@article{Jellinger_1991, title={Pathology of Parkinson’s disease: Changes other than the nigrostriatal pathway}, volume={14}, ISSN={1044-7393}, url={http://dx.doi.org/10.1007/bf03159935}, DOI={10.1007/bf03159935}, number={3}, journal={Molecular and Chemical Neuropathology}, publisher={Springer Science and Business Media LLC}, author={Jellinger, Kurt A.}, year={1991}, month=jun, pages={153–197} }